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Objective: To determine whether oral prednisolone or 
aciclovir, used separately or in combination, early in the 
course of Bell’s palsy, improves the chances of recovery 
at 3 and 9 months.
Design: A 2 × 2 factorial randomised double-blind trial. 
Patients were randomly assigned to treatment by an 
automated telephone service using a permuted block 
randomisation technique with block sizes of four or 
eight, and no stratification.
Setting: Mainland Scotland, with referrals mainly from 
general practice to 17 hospital trial sites.
Participants: Adults (aged 16 years or older) with 
unilateral facial nerve weakness of no identifiable cause 
presenting to primary care, the emergency department 
or NHS24 within 72 hours of symptom onset.
Interventions: Patients were randomised to receive 
active preparations or placebo for 10 days: (1) 
prednisolone (50 mg per day, 2 × 25-mg capsules) and 
aciclovir (2000 mg per day, 5 × 400-mg capsules); (2) 
prednisolone and placebo (lactose, indistinguishable); (3) 
aciclovir and placebo; and (4) placebo and placebo. 
Outcome measures: The primary outcome was 
recovery of facial function assessed by the House–
Brackmann scale. Secondary outcomes included health 
status, pain, self-perceived appearance and cost-
effectiveness.
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Results: Final outcomes were available for 496 
patients, balanced for gender; mean age 44 years; 
initial facial paralysis moderate to severe. One half of 
patients initiated treatment within 24 hours of onset 
of symptoms, one-third within 24–48 hours and the 
remainder within 48–72 hours. Of the completed 
patients, 357 had recovered by 3 months and 80 at 
9 months, leaving 59 with a residual deficit. There 
were significant differences in complete recovery at 3 
months between the prednisolone comparison groups 
(83.0% for prednisolone, 63.6% for no prednisolone, 
a difference of + 19.4%; 95% confidence interval (CI): 
+ 11.7% to + 27.1%, p < 0.001). The number needed 
to treat (NNT) in order to achieve one additional 
complete recovery was 6 (95% CI: 4 to 9). There 
was no significant difference between the aciclovir 
comparison groups (71.2% for aciclovir and 75.7% 
for no aciclovir). Nine-month assessments of patients 
recovered were 94.4% for prednisolone compared with 
81.6% for no prednisolone, a difference of + 12.8% 
(95% CI: + 7.2% to + 18.4%, p < 0.001); the NNT 
was 8 (95% CI: 6 to 14). Proportions recovered at 9 
months were 85.4% for aciclovir and 90.8% for no 
aciclovir, a difference of – 5.3%. There was no significant 
prednisolone–aciclovir interaction at 3 months or at 9 
months. Outcome differences by individual treatment Abstract
iv
(the four-arm model) showed significant differences. 
At 3 months the recovery rate was 86.3% in the 
prednisolone treatment group, 79.7% in the aciclovir–
prednisolone group, 64.7% in the placebo group and 
62.5% in the aciclovir group. At 9 months the recovery 
rates were respectively 96.1%, 92.7%, 85.3% and 
78.1%. The increase in recovery rate conferred by the 
addition of prednisolone (both for prednisolone over 
placebo and for aciclovir–prednisolone over aciclovir) 
is highly statistically significant (p < 0.001). There were 
no significant differences in secondary measures apart 
from Health Utilities Index Mark 3 (HUI3) at 9 months 
in those treated with prednisolone. 
Conclusions: This study provided robust evidence to 
support the early use of oral prednisolone in Bell’s palsy 
as an effective treatment which may be considered cost-
effective. Treatment with aciclovir, either alone or with 
steroids, had no effect on outcome.
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TABLE 1  Study calendar 
Dates Duration Activity
Nov 2003–May 2004 7 months Approvals, staff recruitment and training
Jun 2004–Jun 2006 25 months Recruitment of patients
Jul 2006–Mar 2007 9 months Follow-up of patients
Apr 2007–Jun 2007 3 months Analysis of resultsDOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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FIGURE 2  Posed portrait photographs (at rest, smiling, eyes tight shut, eyebrows raised). Note: This patient was graded HB5 by the 
panel of assessors.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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TABLE 2  Trial sites for the BELLS study
Raigmore Hospital, Inverness
Aberdeen Royal Infirmary




Western General Hospital, Edinburgh
St John’s Hospital, Livingston
Borders General Hospital, Melrose
Crosshouse Hospital, Kilmarnock
Royal Alexandra Hospital, Paisley (two sites: ward and 
annex)
Monklands Hospital, Airdrie







































































































































TABLE 3  Inclusion and exclusion criteria for the BELLS study
Inclusion criteria
Adults (16 or older)
Unilateral facial nerve weakness of no identifiable cause 
confirmed as Bell’s palsy
Seen within 72 hours of the onset of weakness
Exclusion criteria
Pregnancy





Sarcoidosis and other rarer conditions
Inability to give informed consent
Breast-feeding
Patients with systemic infection
HbA1c, glycated haemoglobin.
TABLE 4  BELLS study: factorial trial design







TABLE 5  Dosing regime for the BELLS study
Prednisolone 2 × 25 mg/day = 50 mg/day for  
10 days, starting immediately
Placebo equivalent Indistinguishable capsules (red)
Aciclovir 5 × 400 mg/day = 2000 mg/day for 
10 days, starting immediately
Placebo equivalent Indistinguishable capsules (green)DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 7  Coverage of the BELLS study, showing the proportion of coverage achieved in each region
Region Coverage Proportion
North NHS Highland, NHS Grampian 16.4%
East and South-East NHS Tayside, NHS Fife 16.6%
South NHS Lothian, NHS Lothian West NHS Borders, NHS Dumfries and 
Galloway
17.5%
West NHS Argyll & Clyde, NHS Forth Valley, NHS Greater Glasgow, NHS 
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TABLE 8  Trial objectives for the BELLS study
1. To describe the resolution of neurological deficit and cosmetic, psychological and functional recovery in each of four 
groups of patients: those treated with prednisolone, aciclovir, both, or neither
2. To determine which group of patients has the greatest reduction in neurological disability scores on the House–
Brackmann grading system at 3 and 9 months after randomisation
3. To compare self-reported health status (including assessments of pain) at 3 and 9 months after randomisation
4. To compare the incremental cost per neurological deficit resolved (case cured) and incremental cost per QALY in the 
study groupsMethods
10
TABLE 9  House–Brackmann scale
Grade Definition
I Normal symmetrical function in all areas
II Slight weakness noticeable only on close inspection. Complete eye closure with minimal effort. Slight asymmetry 
of smile with maximal effort. Synkinesis barely noticeable; contracture or spasm absent
III Obvious weakness, but not disfiguring. May not be able to lift eyebrow. Complete eye closure; strong but 
asymmetrical mouth movement with maximal effort. Obvious, but not disfiguring synkinesis, mass movement or 
spasm
IV Obvious disfiguring weakness. Inability to lift brow. Incomplete eye closure and asymmetry of mouth with maximal 
effort. Severe synkinesis, mass movement, spasm
V Motion barely perceptible. Incomplete eye closure; slight movement of corner of mouth. Synkinesis, contracture 
and spasm usually absent
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1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00 1  1.00
2  0.98 2  0.95 2  0.94 2  0.93 2  0.95 2  0.95 2  0.92 2  0.96
3  0.89 3  0.89 3  0.89 3  0.86 3  0.88 3  0.85 3  0.95 3  0.90
4  0.84 4  0.80 4  0.81 4  0.73 4  0.76 4  0.64 4  0.83 4  0.77
5  0.75 5  0.74 5  0.68 5  0.65 5  0.65 5  0.46 5  0.60 5  0.55






















Methods used to enhance 






















TABLE 11  DAS59 scoring system
Factor Label Items
Factor 1 General self-consciousness of appearance (GSC) 1, 8, 10, 12, 15, 17, 27, 28, 30, 31, 
34, 35, 36, 38, 41, 42, 58
Factor 2 Social self-consciousness of appearance (SSC) 2, 3, 5, 6, 7, 13, 14, 16, 18, 19, 20, 
21, 22, 29, 32, 33, 39, 40, 47, 50
Factor 3 Sexual and bodily self-consciousness of appearance (SBSC) 4, 9, 23, 24, 37, 43, 45, 46, 49
Factor 4 Negative self-concept (NSC) 52, 54, 55, 56, 57










the.decoding.key.and.agreed.that.interpretation.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47





































Explanation of any interim 
















































Chapter 3  
Study designStudy design
14
Table 12  Target completed patient numbers in the Scottish Bell’s Palsy Study
Treatment  Prednisolone Placebo  Total 
Aciclovir  AP (120) AO (120) 240
Placebo  OP (120) OO (120) 240
Total  240 240 480
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Figure Number: 4.ai   Title: 02-09-04 Proof Stage:  2
Assessed for eligibility
n = 752
Not meeting inclusion criteria    n = 132
Eligible but refused to participate   n = 59
Enrolment failed (admin error)    n = 6







Received allocation  n = 130
Received alternative  n = 4
(human error, allocation n/a)
Received allocation  n = 135
Received alternative  n = 3
(human error, allocation n/a)
AP (coded treatment 3)
Lost to follow-up
  n = 10
No contact achieved
  n = 0
Patient w/d, trial intrusive
  n = 2
Patient w/d to seek active
treatment
    n = 2
Patient w/d by team
  n = 0
No 1-year data provided
  n = 0
Lost contact after V1
  n = 6
Patient died
  n = 0
TOTAL
  n = 10
Completed n = 124
AO (coded treatment 4)
Lost to follow-up
  n = 15
No contact achieved
  n = 1
Patient w/d, trial intrusive
  n = 2
Patient w/d to seek active
treatment
  n = 1
Patient w/d by team
  n = 1
No 1-year data provided
  n = 0
Lost contact after V1
  n = 9
Patient died
  n = 1
TOTAL
  n = 15
Completed n = 123
OP (coded treatment 1)
Lost to follow-up
  n = 11
No contact achieved
  n = 0
Patient w/d, trial intrusive
  n = 4
Patient w/d to seek active
treatment
  n = 2
Patient w/d by team
  n = 0
No 1-year data provided
  n = 1
Lost contact after V1
  n = 4
Patient died
  n = 0
TOTAL
  n = 11
Completed n = 127
OO (coded treatment 2)
Lost to follow-up
  n = 19
No contact achieved
  n = 3
Patient w/d, trial intrusive
  n = 6
Patient w/d to seek active
treatment
  n = 3
Patient w/d by team
  n = 1
No 1-year data provided
  n = 1
Lost contact after V1
  n = 3
Patient died
  n = 2
TOTAL
  n = 19









Received allocation  n = 135
Received alternative  n = 3




Received allocation  n = 141




FIGURE 4  CONSORT Framework diagram, BELLS study. AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–
placebo group; OP , placebo–prednisolone group; n/a, not available.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 5  Weekly recruitment to the BELLS study.
FIGURE 6  Retention to target on the BELLS study.
TABLE 13  BELLS Study: attained completed patient numbers
Treatment Prednisolone Placebo Total
Aciclovir AP (124) AO (123) A (247)
Placebo OP (127) OO (122) A′ (249)
Total P (251) P′ (245) (496)
A, aciclovir group; A′ no-aciclovir group; AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–
placebo group; OP , placebo–prednisolone group; P , prednisolone group; P′, no-prednisolone group.Results
18
TABLE 14  Attained appointments for the collection of data
Patient health status as defined by House–Brackmann grade
Visit 1  
(soon after onset)
Visit 2  
(~ 3 months after onset)
Visit 3  
(~ 9 months after onset) Frequency
Missed Missed Well 2
Missed Missed Ill 0
Missed Well 8
Missed Ill Well 0
Missed Ill Ill 1
Well Missed Well 1
Ill Missed Well 4
Ill Missed Ill 1
Well Well 30
Ill Well 319
Ill Ill Well 73
Ill Ill Ill 57
Total 496

















































comparison,.and.thus.adjustment.acted.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
19
TABLE 15  Baseline characteristics of randomised treatment groups; mean (SD) or percent (n)
Prednisolone  
P (n = 251)
No prednisolone  
P′ (n = 245)
Aciclovir  
A (n = 247)
No aciclovir  




Male 53.8 (135) 48.2 (118) 48.2 (119) 53.8 (134) 51.0 (253)
Female 46.2 (116) 51.8 (127) 51.8 (128) 46.2 (115) 49.0 (243)




3.5 (1.2) 3.8 (1.3) 3.6 (1.3) 3.7 (1.2) 3.6 (1.3)
Secondary outcome
HUI3b 0.796 (0.225) 0.775 (0.206) 0.792 (0.209) 0.779 (0.223) 0.786 (0.216)
DAS59b 71 (37) 75 (41) 72 (39) 74 (38) 73 (39)
BPIc 10 (18) 16 (21) 12 (18) 14 (21) 13 (20)
Time to commencement of treatment
Within 24 h 47.8 (120) 60.0 (147) 55.5 (137) 52.2 (130) 53.8 (267)
24–48 h 37.8 (95) 26.1 (64) 30.4 (75) 33.7 (84) 32.1 (159)
48–72 h 10.0 (25) 7.3 (18) 10.1 (25) 7.2 (18) 8.7 (43)
Unknown but 
< 72 h
4.4 (11) 6.5 (16) 4.0 (10) 6.8 (17) 5.4 (27)
a  12 missing House–Brackmann grade.
b  13 missing HUI3 (Health Utilities Index Mark 3) and DAS59 (Derriford Appearance Scale 59).
c  Seven missing BPI (Brief Pain Inventory) data.
TABLE 16  Primary outcome at 3 and 9 months unadjusted (u)/adjusted (a)a for baseline characteristics
Treatment % (n) No treatment % (n) OR (95% CI) p value
Prednisolone
HB I at 3 months 83.0% (205/247) 63.6% (152/239) 2.79 (1.82 to 4.35) (u)
2.44 (1.55 to 3.84) (a)
< 0.001 (u)
< 0.001 (a)
HB I at 9 months 94.4% (237/251) 81.6% (200/245) 3.81 (2.01 to 7.56) (u)




HB I at 3 months 71.2% (173/243) 75.7% (184/243) 0.79 (0.53 to1.21) (u)
0.86 (0.55 to 1.34) (a)
0.304 (u)
0.504 (a)
HB I at 9 months 85.4% (211/247) 90.8% (226/249) 0.60 (0.34 to 1.07) (u)
0.61 (0.33 to 1.11) (a)
0.072 (u)
0.105 (a)
a  Adjusted for age, gender, baseline House–Brackmann (HB) grade, aciclovir (Yes/No) and prednisolone (Yes/No) and time 




































































































their.diagnosis..Figure 9.shows.the.proportion.of.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
21
TABLE 17  Proportion of patients making a full recovery (House–Brackmann I) at 3 and 9 months
Treatment 0 months 3 months 9 months
OP 10/127 = 7.9% 107/124 = 86.3% 122/127 = 96.1%
AP 10/124 = 8.1% 98/123 = 79.7% 115/124 = 92.7%
OO 6/122 = 4.9% 77/119 = 64.7% 104/122 = 85.2%
AO 8/123 = 6.5% 75/120 = 62.5% 96/123 = 78.0%
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.
TABLE 18  Proportion of patients making a good recovery (House–Brackmann I or II) at 3 and 9 months
Treatment None
Unadjusted % (n)a Unadjusted % (n)a OR (95% CI) p value
Prednisolone
HB I/II at 3 months 93.9 (232/247) 77.8 (186/239) 4.41 (2.35 to 8.19) <0.001
HB I/II at 9 months 97.2 (244/251) 94.7 (232/245) 1.95 (0.74 to 5.41) 0.176
Aciclovir
HB I/II at 3 months 84.0 (204/243) 88.0 (214/243) 0.71 (0.41 to 1.19) 0.239
HB I/II at 9 months 95.1 (235/247) 96.8 (241/249) 0.65 (0.26 to 1.71) 0.372
a  Adjusted for age, gender, baseline House–Brackmann (HB) grade, aciclovir (Yes/No) and prednisolone (Yes/No) and time to start 
of treatment.
Cactus Design and Illustration Ltd
Figure Number: 7.ai   Title: 02-09-04 Proof Stage:  2
OP: 7.9% (0 months) 86.3% (3 months) 96.1 % (9 months)
AP: 8.1% (0 months) 79.7% (3 months) 92.7 % (9 months)
OO: 4.9% (0 months) 64.7% (3 months) 85.2 % (9 months)





































FIGURE 7  Proportion of patients making a full recovery (House–Brackmann I) at three and 9 months. AO, aciclovir–placebo group; AP , 
aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.Results
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Figure Number: 08.ai   Title: 02-09-04 Proof Stage:  1
OP: 19.0% (0 months) 95.2% (3 months) 98.4 % (9 months)
AP: 12.8% (0 months) 80.7% (3 months) 95.9 % (9 months)
OO: 18.5% (0 months) 92.7% (3 months) 96.8 % (9 months)





































FIGURE 8  Proportion of patients making a good recovery (House–Brackmann I or II) at 3 and 9 months. AO, aciclovir–placebo group; 
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Figure Number: 9.ai   Title: 02-09-04 Proof Stage:  1
OP: 34.4% (0 months) 6.6% (3 months) 13.0% (9 months)
AP: 37.9% (0 months) 8.9% (3 months) 3.7% (9 months)
OO: 59.3% (0 months) 7.6% (3 months) 6.5% (9 months)





































FIGURE 9  Proportion of patients describing themselves as ‘in pain’ at onset, after 3 months and after 9 months. AO, aciclovir–placebo 


























TABLE 19  Number of patients, mean BPI score and SD for the BPI score
Treatment 
group
0 months  3 months 9 months
n Mean SD n Mean  SD n Mean  SD
OP 125 10.9 19.6 122 1.2 5.4 23 1.6 4.1
AP 124 9.9 16.7 123 1.8 7.2 27 1.2 6.0
OO 118 17.6 22.8 118 2.2 9.3 46 1.8 6.9
AO 122 13.8 1.4 120 1.8 6.8 48 1.9 5.7
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.Results
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Figure Number: 10.ai   Title: 02-09-04 Proof Stage:  1
OP: 66.4% (0 months) 14.8% (3 months) 17.4% (9 months)
AP: 65.6% (0 months) 13.1% (3 months) 29.6% (9 months)
OO: 73.5% (0 months) 20.2% (3 months) 25.0% (9 months)





































FIGURE 10  Proportion of patients dissatisfied with appearance. AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, 
placebo–placebo group; OP , placebo–prednisolone group.
TABLE 20  Number of patients, mean DAS59 score and SD for the DAS59 score
Treatment 
group
0 months  3 months 9 months
n Mean  SD n Mean  SD n Mean SD
OP 125 72.0 36.5 121 42.8 32.1 24 30.8 28.8
AP 121 69.8 36.8 122 42.0 32.3 27 48.2 39.1
OO 116 75.7 39.7 117 39.9 28.2 46 49.7 38.1
AO 121 74.6 41.5 120 46.5 37.3 47 50.0 32.3
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.
TABLE 21  Number of patients, mean HUI3 score and SD for the HUI3 score
Treatment 
group
0 months  3 months 9 months
n Mean  SD n Mean  SD n Mean SD
OP 125 0.80 0.24 121 0.92 0.16 22 0.83 0.25
AP 124 0.80 0.21 121 0.90 0.18 27 0.85 0.26
OO 114 0.76 0.20 117 0.91 0.12 46 0.90 0.15
AO 120 0.79 0.21 119 0.90 0.13 47 0.86 0.17
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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TABLE 22  Estimates of key outcome measures for the non-parametric Kaplan–Meier fit
Treatment
Lower quartile time 
to full recovery (days)
Median time to full 
recovery (days)
Upper quartile time 
to full recovery (days)
Mean time to full 
recovery (days)
OP 20 45 77 67
AP 24 54 87 85
OO 34 71 174 126
AO 40 79 240 150
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.
TABLE 23  Number of adverse events by treatment group
OP AP OO AO Total
Dizziness 5 4 4 5 18
Dyspepsia 2 4 3 1 10
Nausea 1 2 3 3 9
Constipation 3 2 1 0 6
Hunger 1 1 0 2 4
Vomiting 0 2 1 0 3
Insomnia 1 1 1 0 3
Night sweats 2 1 0 0 3
Rash 0 1 0 2 3
Hot flushes 1 1 0 0 2
Depression 0 0 0 1 1
Thirst 0 0 1 0 1
Anorexia 0 1 0 0 1
Diarrhoea 0 0 0 1 1
Drowsiness 0 0 1 0 1
Pruritus 0 1 0 0 1
Combinations of minor 
symptomsa
8 4 3 3 18
Subtotal 24 25 18 18 85
Death 0 0 2 1 3
Total 24 25 20 19 88
AO, aciclovir–placebo group; AP , aciclovir–prednisolone group; OO, placebo–placebo group; OP , placebo–prednisolone group.
a  Combinations of minor symptoms: Patients exhibiting two or more symptoms (e.g. dizziness and vomiting) are shown in this 
row only and not duplicated in rows corresponding to a separate entry (i.e. dizziness, vomiting).
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FIGURE 12  Bell’s palsy decision tree model: prednisolone vs no prednisolone.
Cactus Design and Illustration Ltd
Figure Number: 12.ai   Title: 02-09-04 Proof Stage:  1
Cured at 3 months
Cured at 9 months
Not cured at 9 months
Not cured at 9 months
Not cured at 3 months
Not cured at 3 months
Cured at 9 months
Cured at 9 months
Cured at 3 months
Cured at 3 months
No prednisolone
Prednisolone
Cured at 3 months





FIGURE 13  Decision tree model for early treatment for Bell’s palsy: prednisolone alone vs aciclovir alone vs prednisolone + aciclovir vs 
no treatment (placebo).
Cactus Design and Illustration Ltd





Cured at 3 months
Identical subtree structures
for all decision branches
Cured at 3 months
Cured at 9 months
Not cured
Not cured at 3 months
Estimated costs
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PD assumed for 
difference
Probability of being cured at 3 months 0.71 0.76 – 0.05 (– 0.12 to 
0.03)
Normal
Probability of being cured at 9 months 
given not cured at 3 months
0.49 0.61
PD, probability distribution.






Probability of being cured at 
3 months
0.83 0.64 0.19 (0.12 to 0.27) Normal
Probability of being cured at 









Probability of being cured at 3 
months (SE)
0.84 (0.03) 0.60 (0.04) 0.78 (0.04) 0.65 (0.04)
Probability of being cured at 
9 months given not cured at 3 
months (SE)
0.71 (0.11) 0.44 (0.07) 0.68 (0.09) 0.57 (0.08)
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TABLE 27  Treatment resource use and costs
Drug Dose Cost Note BNF web pagea
Prednisolone 50 mg/day 
× 10 days
4.32 Prednisolone
Tablets, 25 mg, 56-tab pack = £12.09
http://www.bnf.org
Aciclovir 2000 mg/day 
× 10days
6.57 Aciclovir
Tablets, 400 mg, 56-tab pack = £7.31; 
800 mg, 35-tab pack = £9.22
http://www.bnf.org











Primary and secondary care resource use 
for the two-arm comparisons drawn in the 
trial
This.is.shown.in.Tables 28.and.29.
Primary and secondary care resource use 
for the four arms of the trial
This.is.shown.in.Tables 30–32.





















n 42 42 40 32 33 31
Mean (SD) 3.07 (4.47) 0.07 (0.34) 0.88 (1.84) 1.78 (2.25) 0.12 (0.33) 0.65 (1.05)
Median [IQR] 2 [0–4] 0 [0–0] 0 [0–1] 1 [0–2.5] 0 [0–0] 0 [0–1]
IQR, interquartile range.





















n 48 48 46 26 27 25
Mean (SD) 2.25 (2.67) 0.08 (0.28) 0.74 (1.36) 3 (5.15) 0.11 (0.42) 0.84 (1.86)
Median [IQR] 2 [0–3] 0 [0–0] 0 [0–1] 1 [0–3] 0 [0–0] 0 [0–0]
IQR, interquartile range.Economic evaluation of treatments
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TABLE 30  Health-care resource use by main cost categories: four arms of the trial




















n 22 22 21 16 16 15
Mean (SD) 1.77 (1.88) 0.14 (0.35) 0.62 (0.8) 3.75 (6.09) 0.13 (0.5) 0.93 (2.12)
Median [IQR] 1 [0–3] 0 [0–0] 0 [0–1] 2 [0.5–4.5] 0 [0–0] 0 [0–1]
IQR, interquartile range.
TABLE 31  Health-care resource use by main cost categories. Four arms of the trial




















n 10 11 10 25 25 25
Mean (SD) 1.8 (3.05) 0.09 (0.3) 0.7 (1.49) 2.76 (3.19) 0.04 (0.2) 0.84 (1.7)
Median [IQR] 1 [0–2] 0 [0–0] 0 [0–0] 2 [1–4] 0 [0–0] 0 [0–1]
IQR, interquartile range.












from.Unit costs of health and social care36.(see.Table 
33)..These.unit.costs.were.applicable.to.both.the.
two-arm.and.four-arm.models.
Unit costs of health and social 
care
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Range (£) Interquartile range (£)
Min. Max. p25 p75
Cured (at 3 months) 53 29.13 59.56 0 365.91 0 34.32
Not cured (at 3months) 20 113.17 274.66 0 1205.02 0 48.06
TABLE 33  Unit costs for hospital-based services and primary care services
Service/ward Unit Cost per unit £2005/06 Note
Hospital costs
General Medicine Day case 309 ISD35 Table R042 
General Medicine Day 1061 ISD35 Table R040 
General Surgery  Day case 506 ISD35 Table R042 
General Surgery  Day 1671 ISD35 Table R040 
General Practice Day case 243 ISD35 Table R042 
Hospital outpatient costs
A&E Visit 64 ISD35 Table R044 
Acute Services Visit 238 ISD35 Table R044 
Dermatology Visit 66 ISD35 Table R044 
ENT Visit 74 ISD35 Table R044 
Gastroenterology Visit 142 ISD35 Table R044 
Mental Health Visit 98 ISD35 Table R044 
Neurology Visit 131 ISD35 Table R044 
Occupational Therapist Visit 34 ISD35 Table R046 
Ophthalmology Visit 52 ISD35 Table R044 
Orthopaedics Visit 79 ISD35 Table R044 
Physiotherapy Visit 19 ISD35 Table R046 
Radiology Visit 32 ISD35 Table R046 
Speech Therapist Visit 49 ISD35 Table R046
Urology Visit 65 ISD35 Table R044
Health-Care Assistant Visit 24 ISD35 Table R045
Primary care costs
General Practice Visit 23 PSSRU36 Table 9.8b General practitioner, p. 143 
General Practice Telephone 
consultation
25 PSSRU36 Table 9.8b General practitioner, p. 143 
Practice Nurse Visit 8 PSSRU36 Table 9.6 Nurse (GP practice), p. 140
Practice Nurse Telephone 
consultation
8 PSSRU36 Table 9.6 Nurse (GP practice), p. 140
District Nurse Visit 18 PSSRU36 Table 9.1 Community nurse (includes 
district nursing sister, district nurse), p. 135
Community Therapy Services Visit 14 Assumed same as above Therapists Services36
Health Visitor Visit 31 PSSRU36 Table 9.3 Health visitor, p.137
A&E, accident and emergency; ENT, ear, nose and throat; ISD, information services department; PSSRU, Personal Social 
Services Research Unit.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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TABLE 35  Regression analysis results for total follow-up costs
Dependent variable total costa
Coefficient SE 95% CI
Constant 210 58.39 93.28 to 326.32
Not cured at 3 months 105 112.08 – 118.59 to 328.73
a  n = 70.
TABLE 36  HUI3 regression analysis for 3 and 9 months cured and not cured utility weights
Dependent variable: HUI3 at 3 months
Number of obs = 487
Coefficient SE 95% CI
Constant 0.6146 0.0235 0.5684 to 0.6609
Cured 0.0574 0.0132 0.0314 to 0.0834
Dependent variable: HUI3 at 9 months
Number of obs = 137
Coefficient SE 95% CI
Constant 0.5265 0.0495 0.4287 to 0.6243
Cured – 0.0019 0.0293 – 0.0599 to 0.0561
Utility weights (mean values)
Cured at 3 months Cured at 9 months Not cured
0.9947 0.9900 0.9919
Baseline characteristics: HUI3 data all participants
Mean = 0.786 SD = 0.216
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TABLE 37  Deterministic cost-effectiveness results. Prednisolone vs No prednisolone model
Treatment Cost (£) Cured casesa at 9 months (%) ICERb
Prednisolone 231.98 94.4%
No prednisolone 248.05 81.6% Dominated
a  Cured cases defined as HB score = 1.
b  incremental cost-effectiveness ratio.
TABLE 38  Cost-effectiveness results. Prednisolone vs No prednisolone model
Treatment  Cost (£)  QALYs  ICER 
Probability that intervention is cost-effective for different 
threshold values for society’s willingness to pay for a QALY 
10,000 20,000 30,000 50,000
Prednisolone 231.98 0.718 79.3% 77.5% 77.0% 76.0%
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Figure Number: 14.ai   Title: 02-09-04 Proof Stage:  1
–0.015 –0.010 –0.005 –0.000 0.005 0.010
Incremental QALYs
Prednisolone vs no prednisolone
Average
































FIGURE 14  Incremental cost-effectiveness scatterplot. Prednisolone vs no prednisolone model.
Cactus Design and Illustration Ltd
Figure Number: 15.ai   Title: 02-09-04 Proof Stage:  2
Prednisolone
No prednisolone
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FIGURE 15  Cost-effectiveness acceptability curves. Prednisolone vs no prednisolone model.
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TABLE 39  Deterministic cost-effectiveness results: Aciclovir vs No aciclovir model
Treatment Cost (£) Cured casesa at 9 months (%) ICER
No aciclovir 235.33 90.8%
Aciclovir 246.63 85.4% Dominated
a  Cured cases defined as HB score = 1.
ICER, incremental cost-effectiveness ratio.
TABLE 40  Cost-effectiveness results: Aciclovir vs No aciclovir model
Treatment
Probability that intervention is cost-effective for different 
threshold values for society’s willingness to pay for a QALY
Cost (£) QALYs ICER 10,000 20,000 30,000 50,000
No aciclovir 235.33 0.718 91.1% 85.1% 82.2% 79.0%
Aciclovir 246.63 0.717 Dominated 8.9% 14.9% 17.8% 21.0%







Comparison of all four 
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Figure Number: 16.ai   Title: 02-09-04 Proof Stage:  1
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Average
Aciclovir vs no aciclovir
0.002
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FIGURE 16  Incremental cost-effectiveness scatterplot. Aciclovir vs no aciclovir model.Economic evaluation of treatments
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FIGURE 17  Cost-effectiveness acceptability curves. Aciclovir vs no aciclovir model.
Cactus Design and Illustration Ltd
Figure Number: 17.ai   Title: 02-09-04 Proof Stage:  2
Aciclovir
No aciclovir
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TABLE 41  Deterministic cost-effectiveness results. Four-arms model
Treatment Cost (£) Cured casesa at 9 months (%) ICERb
Prednisolone  230.61 96.1%
Aciclovir and prednisolone 244.02 92.7% Dominated
No treatment (placebo) 246.47 85.6% Dominated
Aciclovir  258.93 78.0% Dominated
a  Cured cases defined as HB score = 1.
b  incremental cost-effectiveness ratio.
TABLE 42  Results of cost–utility analysis
Treatment Cost (£) QALYs ICER
Probability that intervention is cost-effective for different 
threshold values for society’s willingness to pay for a QALY
10,000 20,000 30,000 50,000
Prednisolone  230.62 0.719 79.1% 77.4% 76.9% 75.9%
Aciclovir and 
prednisolone
244.02 0.718 Dominated 0.0% 0.0% 0.0% 0.1%
No treatment 246.47 0.717 Dominated 12.5% 9.5% 7.2% 5.2%
Aciclovir  258.93 0.716 Dominated 8.4% 13.1% 15.9% 18.8%
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Cactus Design and Illustration Ltd
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Outcome dependent on the 













































Chapter 6  
Subgroup analyses
TABLE 43  Recovery rates at 3 months vs delay to commencement of treatment
Delay 0–24 hours 24–48 hours 48–72 hours
P 90/115 (0.78) 81/93 (0.87) 20/23 (0.87) 191/231 (0.83)
P′ 84/142 (0.59) 45/63 (0.71) 13/17 (0.76) 142/222 (0.64)
174/257 (0.68) 126/156 (0.81) 33/40 (0.83) 333/453 (0.74)
P , prednisolone group; P′, no-prednisolone group.
TABLE 44  Recovery rates at 9 months vs delay to commencement of treatment
Delay 0–24 hours 24–48 hours 48–72 hours
P 111/117 (0.9487) 90/94 (0.9574) 23/23 (1) 224/234 (0.9573)
P′ 118/146 (0.8082) 55/63 (0.8730) 15/17 (0.8824) 188/226 (0.8319)
229/263 (0.8707) 145/157 (0.9236) 38/40 (0.9500) 412/460 (0.8957)
P , prednisolone group; P′, no-prednisolone group.Subgroup analyses
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TABLE 45  Recovery rates at 9 months
Severity at onset P P′
Moderate (HB II–IV) 169/176 (0.9602) 122/145 (0.8414) 291/321 (0.9065)
Severe (HB V–VI) 42/49 (0.8571) 59/80 (0.7375) 101/129 (0.7829)
211/225 (0.9378) 181/225 (0.8044) 392/450 (0.8711)
P , prednisolone group; P′, no-prednisolone group.
TABLE 47  Assessors’ consistency (intra-rater reliability)
Assessor Same grading Same grading ± 1 Difference ≥ 2 Cohen’s kappa
J1 80 12 0 0.83
J2 71 21 0 0.70
J3 71 21 0 0.71
J, Judge.
TABLE 46  Assessors’ concordance (inter-rater reliability)
Pairing Unanimous Agreement ± 1 Reassessment Cohen’s kappa
J1 with J2 750 388 34 0.53
J1 with J3 722 395 55 0.50
J2 with J3 769 355 48 0.54
J, Judge.
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2  Planned investigation
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(f)  Ethical arrangements




























































TABLE 1  Sample size required to show various differences in percent with incomplete recovery at 9 months with 80% power at the 5% 
significance level (two-sided)
Trt 1 Trt 2
% incomplete recovery % incomplete recovery Difference Relative risk n per group Total
22% 32% 10% 0.69 328 656
22% 34% 12% 0.65 235 470
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started by ENT registrars
within 48 hours









3 and 9 months  120 120 120 120
Prednisolone only
n =180




















































I Normal symmetrical function in all areas
II Slight weakness noticeable only on close 
inspection. Complete eye closure with minimal 
effort. Slight asymmetry of smile with maximal 
effort. Synkinesis barely noticeable; contracture, 
or spasm absent
III Obvious weakness, but not disfiguring. May not 
be able to lift eyebrow. Complete eye closure 
and strong but asymmetrical mouth movement 
with maximal effort. Obvious, but not disfiguring 
synkinesis, mass movement or spasm
IV Obvious disfiguring weakness. Inability to lift brow. 
Incomplete eye closure and asymmetry of mouth 
with maximal effort. Severe synkinesis, mass 
movement, spasm
V Motion barely perceptible. Incomplete eye 
closure, slight movement corner mouth. 
Synkinesis, contracture, and spasm usually absent



























Measure Baseline 3 months 9 months
House–
Brackmann
720   576   138  
Health Utilities 
Index
720   576   504  
Chronic Pain 
Grade
720   576   504  
Costs 720   576   504  
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3  Project timetable and milestones
Month Activity
– 3   MREC Submission
Inform practices via local research, teaching and 
training networks, the MRC GP Research Framework, 
two direct mailshots to every medical and dental 
practice and out of hours co-operatives in Scotland. 
Train NHS24 nurses and ENT registrars. General 
advertisement via medical press
1   Project-specific training of research team to use 
study instruments
Pilot study instruments and recruitment process
2   Begin patient recruitment. Monthly reminders 
to health professionals. Data entry by research 
secretary
5   Begin 3-month assessments
6   Provide first interim report and prepare 
conference submissions
11   Begin 9-month assessments
12   Provide second interim report
18   Complete patient recruitment. Provide third 
interim report
21   Complete 3-month assessments
24   Provide fourth interim report
27   Complete 9-month assessments. Final analysis 
and writing up



























































































It is crucial to the design of the trial that the time delay 
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25.. Information.and.Statistics.Division..ISD Scotland 
Guide: an A-Z of the work of the Information & Statistics 
Division..Edinburgh:.Information.&.Statistics.
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Template for Trial Steering 
























Proposed date for end of 
recruitment
Actual recruitment rate 
vs target rate (by month/
quarter)
Acceptance rate, as a 
proportion (i) of those 
invited to participate
(ii) of all eligible 
participants, if known
Quarterly/monthly 
forecasts of recruitment 
for the planned 
remainder of the trial
Losses to follow-up (i) 
as a proportion of those 
entered
(ii) per month/quarter
Number still being 
followed up successfully 
and number who have 
completed follow-up
Completeness of data 
collected




Issues specific to the trial 
(as specified by the TSC)
Please include a graph plotting the cumulative target and 
achieved recruitment numbers against time since start of 
recruitmentDOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47






















































































Appendix 3  












Output and reporting by DMEC 
group
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DATA MONITORING AND ETHICS COMMITTEE
REPORT TEMPLATE 1






















All serious adverse events, as defined below, must be reported to the lead clinician of the DMEC monitoring subgroup 
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To be summarised here but reported immediately to the Chairs of the DMEC subgroup and ethics committee and if 
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Approvals from local committees
















questions.about.the safety of steroid medication..
There.were.some.considerable.delays.induced.by.
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Timetable of approvals
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TABLE 48  Approvals process from letter of award
Item Number of applications Time taken
MREC approval 1 + revision 15 weeks
MHRA (DDX certificate) 1 4 weeks
University agreements 4 4 months
University sponsorship 2 months after identification of this item as an issue
NHS contracts 4 × 4 Variable – some came back by return of post
Local ethics approvals 18 5 months. By the time the last two applications were 
made the form and associated requirements had 
altered
R&D approvals 22 5 months. Some took less than 3 weeks (including 
Christmas closure)
Pharmacies 17 Altogether about 6 weeks, with most taking 2 weeks 
on average
DDX, Doctors’ and Dentists’ Exemption; MHRA, Medicines and Healthcare Products Regulatory Agency; MREC, 
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The NHS has asked us to find out whether either of these medicines, separately or together, is most helpful in 
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When do I need to decide?
•. We.think.that.if.these.medicines.are.effective,.then.they.have.to.be.taken.early,.preferably.within.48.
hours.of.you.first.noticing.your.condition.and.definitely.within.72.hours.
•. So, please let us know very soon if you are happy to join the study so that treatment can commence. Preferably, tell 
the doctor that gave you this information sheet now.












obtained.from.<.contact name and details.>..The.results.of.this.study.will.be.published.in.medical.journals..
An.internal.report.will.be.written.on.completion.of.the.study.in.2006.and.will.be.distributed.to.all.taking.
part.in.it..Individuals.will.not.be.identified.in.any.report.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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case record form 
Form A 
v.8 dated 19th April 2004 
Patient number 
(allocated by HSRU) 
2 6 0 4  __  __  __ 
 
 
To be completed by the consultant/ registrar/ SHO on arrival of any patient presenting at the 
Acute Receiving Clinic with a possible Bell’s Palsy. 
Section 1    This section is to be completed for all patients. 
Patient name 
title  forename  surname 
Address 
 
     
postcode 
Telephone 
day  evening  mobile 
 
Date of birth 
day / month / year  Sex 
m/f 
Who sent the patient here? 
e.g. GP / A&E / NHS24 / dentist / patient’s own decision / other 
Name (consultant/registrar/SHO) 
title  initial(s)  surname 
 
In your opinion does this patient have Bell’s palsy? 
yes  no 
 
If your answer is NO, complete the next box, sign and date the form and STOP. File the form. 
Otherwise, leave the next box entirely BLANK and proceed directly to Section 2. 
Diagnosis   
Signature and date 
signature  date 
 
Section 2    To be completed for all patients presenting with a confirmed diagnosis of Bell’s Palsy 
Is the patient already on a trial?  no  yes 
Is the patient aged 16 or more today?  no  yes 
Did the patient become aware of symptoms less than 72 hours ago?  no  yes 
Could the patient be pregnant?  no  yes 
Is the patient breast-feeding?  no  yes 
Is the patient diabetic?  no  yes 
Does the patient have any of the following conditions? 
A systemic infection  no  yes  An active peptic ulcer  no  yes 
Suppurative otitis media  no  yes  Herpes zoster  no   yes 
Multiple sclerosis  no  yes  Sarcoidosis or a similar condition  no  yes 
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If any shaded box in the preceding table has been ticked, complete the next box, sign and date the form, and 
STOP. File the form. Otherwise, leave the next box entirely BLANK and proceed directly to Section 3. 
This patient does not fulfil the criteria for entry into the BELLS study and is excluded. 
The treatment I have prescribed for the diagnosed condition of Bell’s palsy is given here. 
treatment prescribed 
Signature and date 
signature  date 
 
Section 3    To be completed for all patients eligible for entry into the BELLS study 
Please ensure the patient has read the Patient Information Sheet for the BELLS study, and has had the 
opportunity to discuss its contents with an informed person (e.g. their GP, yourself, the clinic nurse). 
If the patient declines to enter the study, despite being eligible, complete the next box, and STOP. File the 
form. Otherwise, leave the next box entirely BLANK and proceed directly to complete the rest of the form. 
This patient is eligible for entry to the BELLS study, but has declined. 
I have indicated the treatment I have prescribed for this patient. 
It is not necessary for the patient to provide a reason for their decision not to enter the study, but if a 
reason was given, please record it here. 
treatment prescribed 
reason for decision 
Signature and date 
signature  date 
 
For any patient agreeing to enter the study, the Consent Form provided for the BELLS study MUST be 
initialled, signed and dated appropriately by the patient and by the consenting clinician. Then attach the 
completed Consent Form to this sheet of paper. Please now call the randomisation centre at HSRU on 
0800 000000 
giving your centre number 
2604 (Perth Royal Infirmary) 
for the allocation of patient number and treatment. Please complete, sign and date the final box following. 
Then file both forms. 
I have telephoned HSRU at Aberdeen and given the name, address and telephone number of this 
patient and advised them that the patient is a new entry to the Scottish Bell’s Palsy Study. The patient 
number and the treatment given to the patient is that allocated by HSRU during the call, and I have 
recorded the patient number and allocated treatment below. 
I have supplied the patient with two bottles containing the allocated treatment. I have recorded the 
patient number on both bottles. 
Patient number (allocated by HSRU) 
 
2 6 0 4  __  __  __ 
1 or 2 or 3 or 4 
Signature and date 
signature  date 
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Scottish Bell’s Palsy Study  Consent Form  v.6 dated 18th November 2003 
 
 
Scottish Bell’s Palsy Study 
‘BELLS’ 
Consent Form 
  Initials 
I confirm that I have read and understand the BELLS Patient Information 
Sheet, and that I have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary, and that I am free to 
withdraw from the study at any time, without giving any reason, and 
without my medical care or legal rights being affected. 
 
I understand that sections of my medical notes may be looked at by 
responsible persons associated with the study, or by regulatory authorities 
where it is relevant to my taking part in the research. I give permission for 
these persons to have access to my records. 
 
I understand that I may be approached for follow-up information, after my 
final assessment visit, by responsible persons associated with the study, 
and I give permission for such an approach to be made. 
 




Name of patient (print) 
 
 
Date  Signature 
Name of person taking consent (who 
should witness the patient’s signature) 
 
Date  Signature 
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Scottish Bell’s Palsy Study 
‘BELLS’ 
24-hour Randomisation Service User Guide 
The purpose of the Bell’s Palsy Study Randomisation Service run by HSRU Aberdeen is 
(i) to allocate a patient ID and (ii) to allocate a treatment 
for patients participating in the Scottish Bell’s Palsy Study. 
The number of the Randomisation Service is 0800 000000*. Before you begin you will need your 
centre number which is 2 6 0 3 and should have immediately available your patient’s name, 
address and telephone number. 
After dialling the number, the call should proceed as follows. 
Prompt  Your response 
Welcome to the Aberdeen Trials Service. Please 
enter your Centre Number or Trial ID Code.   
2603 
This is the Bell’s Palsy Study. Your trial centre 
is < speaks hospital name >. 
Press 1 to continue or 2 to modify.   
Example 1 
Please speak the patient’s name, address and 
contact telephone number after the tone, then 
press the star key.   
Example Mr Charles Bell, 
47 Kirsty Semple Way, 
Dundee DD4 8HZ, 




You said < repeats spoken patient details >. 
Press 1 to continue or 2 to modify.   
Example 1 
The allocated patient number is 
< utters seven digits such as 2603011 >. 
Please confirm the patient number by dialling it 
on the telephone keypad after the tone. 
 
Example 2603011 
The allocated treatment is treatment number 
< utters a single digit 1 2 3 or 4 >. 
Please confirm the treatment number by dialling 
it on the telephone keypad after the tone. 
 
Example 3 
Thank you for calling the 
Bell’s Palsy Study Randomisation Service. 
Please hang up now. 
Hang up 
Complete Form A 
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What to do if the call fails 
If the call fails, then during office hours you should call 
01224 000000 / 000000 
for human assistance. If this call also fails, or if the allocation is required outside office hours, then 
you should proceed as follows. 
(i)  Do not worry about allocating the patient ID: this number will be determined later by 
the study researcher. 
(ii)  Determine the allocated treatment by choosing at random a single digit from the list 
below. 
4  1  3  4  2  4  2  3  1  1  2  4  4  3  1  3  2  1  2  2  4  1  3  1  4 
1  3  1  3  1  4  2  2  3  3  1  4  3  1  1  4  1  4  1  1  3  3  1  1  2 
1  2  2  3  1  3  3  2  2  3  4  4  1  3  4  2  1  2  3  2  2  3  1  3  2 
4  4  2  3  4  4  2  3  3  2  1  2  3  2  1  3  2  3  2  1  3  3  3  2  3 
4  3  3  1  2  4  3  4  3  3  3  3  1  4  3  2  1  2  4  1  3  3  2  3  1 
2  1  1  2  4  2  3  2  2  2  3  4  1  3  2  3  1  4  3  2  2  1  3  3  4 
4  4  1  2  4  3  1  2  1  3  2  2  2  3  2  4  1  4  3  4  2  1  3  3  3 
1  2  1  3  2  1  4  3  1  4  2  3  1  4  2  1  1  4  2  1  2  1  1  3  2 
3  2  3  3  3  4  3  4  4  4  1  2  1  2  1  3  1  2  2  1  4  3  2  1  2 
2  1  3  2  1  4  4  1  3  2  3  2  2  4  3  4  1  4  3  3  4  4  1  1  3 
1  3  2  4  1  2  2  3  3  1  4  2  3  2  1  4  4  1  4  4  4  4  4  2  1 
1  1  2  4  3  1  1  1  1  1  1  3  4  4  2  4  2  4  2  1  1  2  3  4  1 
2  2  2  4  4  4  3  1  1  3  4  2  3  4  3  1  3  1  4  2  3  2  1  1  2 
3  1  1  3  1  1  1  1  4  1  3  2  2  3  2  1  2  3  3  1  2  3  1  3  3 
3  1  2  1  4  4  2  4  1  2  1  2  2  4  1  4  3  2  4  2  1  3  2  4  4 
1  4  3  3  1  1  3  1  2  4  3  2  2  2  2  2  4  1  3  3  2  4  3  1  4 
4  1  1  1  3  4  1  2  4  4  3  2  2  3  4  1  2  2  4  4  1  1  3  1  4 
2  2  4  3  4  3  4  1  2  3  4  1  1  1  3  3  4  3  2  2  2  1  4  4  2 
2  1  2  1  2  3  4  3  3  3  3  1  4  4  2  2  4  4  2  4  1  4  4  1  4 
3  2  2  1  4  2  1  3  3  1  4  2  2  3  4  2  4  2  2  3  2  4  1  3  3 
 
(iii)  Please advise the BELLS Coordinator IMMEDIATELY that a new patient has been 
recruited, and provide the patient’s name, address and telephone number: 
f.daly@tcgp.dundee.ac.uk 
01382 000000 (W) / 01738 000000 (H) / 0771 000 0000 (M) DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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Two things might go wrong:
•. If for some reason the allocated treatment pack is not available to you, please do not make a 2nd call to HSRU; 
simply allocate at random from the treatments available to you and note your decision on Form A.
•. If the call fails altogether, then again please simply allocate at random from the treatments available to you and 
note your decision on Form A.
In.either.case.and.as.soon.as.you.can,.please.telephone.the.study.co-ordinator.on
01382 000000 (W)  0771 000 000 (M)  01738 000000 (H)
and.say.what.has.happened.
Finally,.please
issue.designated.treatment.and commence dose immediatelyDOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Dear.PIs,.RAs:
BELLS: weekly recruitment update
Week number 81 (16.12.2005 – 23.12.2005)
of.108.recruitment.weeks..The.current.figures.for.the.BELLS.study.are.always.to.be.found.at.http://www.
dundee.ac.uk/bells/index_files/stoppress.htm.
Part 1 Recruitment 
The.cumulative.regional.figures.showing.last.week’s.recruits.are
Grampian and Highland  + 2 76
Tayside and Fife  + 0 67
Lothian and Borders  + 1 73
Glasgow and the West  + 3 198
Total  + 6 414
of.which.M.:.F.=.209.:.205.
FIGURE 1  Weekly recruitment figures showing underlying recruitment rate.
Cactus Design and Illustration Ltd
Figure Number: 22.ai   Title: 02-09-04 Proof Stage:  2
Actual
Trend

































Part 2 Retention and adherence to target
There.were.0.patients.lost.to.follow-up.this.week..Since.the.start.of.the.project.23.patients.have.been.LTF,.
so.there.are.391.patients.‘live’.on.the.study..The.study.is.currently
1 patient below target/1 day behind schedule.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47





FIGURE 2  Retention and target.
Cactus Design and Illustration Ltd
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Part 5 Status of the study
Recruited, awaiting V1  3
V1 made, awaiting V2  70
V2 made, awaiting V2HB  90
V2HB known, V3 not necessary  150
V2HB known, awaiting V3  0
V3 made, awaiting V3HB  42
V3HB known  27
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advise the other RAs by email that you have picked up responsibility for the call
contact the patient and arrange your first visit
At.this.first.visit.you.will.need.to
complete Form B
get the patient to complete three questionnaires














Zoom:.suggest.3.0,.but.local.conditions.may.varyDOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47















BELLS. ID2708033. 20040518. V2. Pose3.jpg
If.you.are.uncertain/unhappy.with.any.of.the.poses.then.it.is.OK.to.send.more.than.one,.but.we.should.try.
not.to.send.more.than.two..In.such.a.case.please.call.the.pose.numbers.Pose3a.and.Pose3b.DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
107
Appendix 15  
Form CAppendix 15
108






(allocated by HSRU) 
2  6  __  __  __  __  __   
 
To be completed by the researcher at (or soon after) all assessment visits including the first 
The following should occur as soon as possible after notification of recruitment 
Copy Form A and Consent Form at site; extract originals and leave copy 
Visit number and date and approx duration 
The following should occur during your visit 
HUI3 completed (all visits)  DAS59 completed (all visits) 
BPI completed (all visits)  4 poses photographed (all visits) 
Provide own contact details (V1)  Issue stamped Jiffy bag (V1) 
Check labelling on bottle (V1)  Arrange next appointment (V1 and V2) 
The following should occur as soon as possible after your visit is completed 
Letter to GP 
Letter to patient (acknowledgement of recruitment/ cooperation; reminder of next appt) 
HUI3 copied and stored locally, original despatched to TCGP 
BPI copied and stored locally, original despatched to TCGP 
DAS59 copied and stored locally, original despatched to TCGP 
Photographs emailed to TCGP 
j.sutherland@dundee.ac.uk 
The following should occur after Visit 1 
Phone call to patient (day 4–6 as convenient: compliance; well-being) 
Phone call to patient (day 10, to confirm end of treatment; ‘Jiffy bag’ reminder; well-being) 
 
 
Summary of paper management 
After Visit 1  despatch originals of Form A, Consent Form and Form B to TCGP, keep copies 
 
After all visits  send letters to GP and patient, keep copies 
    despatch original completed questionnaires to TCGP, keep copies 
    email photographs to TCGP DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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(allocated by HSRU) 
2  6  __  __  __  __  __   
 
To be completed by the researcher at the patient’s first assessment visit 




sex  date of birth 
marital status 
mother’s maiden name 
Other details required for 
General Register Office 
for Scotland 



















Email address   
Consent details 
date of consent  age at consent 
Details of onset 
date / time (approx)  symptoms 







start date  end date 
Arrangements for 3-
month visit 
date / time  place 
Researcher 
name  today’s date DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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Scottish Bell’s Palsy Study 
 
HEALTH  UTILITIES  INDEX: 
 
Multi-Attribute Health Status Classification System 





Patient name     
 
Patient ID    _ _ _ _ _ _ _  
 
Date     
 
Assessment visit no.     
 
Researcher     
 
 
For the given attribute, circle the most appropriate level. 




1  Able to see well enough to read ordinary newsprint and recognize a friend on 
the other side of the street, without glasses or contact lenses. 
2  Able to see well enough to read ordinary newsprint and recognize a friend on 
the other side of the street, but with glasses. 
3  Able to read ordinary newsprint with or without glasses but unable to recognize 
a friend on the other side of the street, even with glasses. 
4  Able to recognize a friend on the other side of the street with or without glasses 
but unable to read ordinary newsprint, even with glasses. 
5  Unable to read ordinary newsprint and unable to recognize a friend on the other 
side of the street, even with glasses. 
6  Unable to see at all. 
 DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47





1  Able to hear what is said in a group conversation with at least three other 
people, without a hearing aid. 
2  Able to hear what is said in a conversation with one other person in a quiet 
room without a hearing aid, but require a hearing aid to hear what is said in a 
group conversation with at least three other people. 
3  Able to hear what is said in a conversation with one other person in a quiet 
room with a hearing aid, and able to hear what is said in a group conversation 
with at least three other people, with a hearing aid. 
4  Able to hear what is said in a conversation with one other person in a quiet 
room, without a hearing aid, but unable to hear what is said in a group 
conversation with at least three other people even with a hearing aid.  
5  Able to hear what is said in a conversation with one other person in a quiet 
room with a hearing aid, but unable to hear what is said in a group conversation 
with at least three other people even with a hearing aid. 





1  Able to be understood completely when speaking with strangers or friends. 
2  Able to be understood partially when speaking with strangers but able to be 
understood completely when speaking with people who know me well. 
3  Able to be understood partially when speaking with strangers or people who 
know me well. 
4  Unable to be understood when speaking with strangers but able to be 
understood partially by people who know me well. 
5  Unable to be understood when speaking to other people (or unable to speak at 
all). 





1  Able to walk around the neighbourhood without difficulty, and without walking 
equipment. 
2  Able to walk around the neighbourhood with difficulty; but do not require 
walking equipment or the help of another person. 
3  Able to walk around the neighbourhood with walking equipment, but without 
the help of another person. 
4  Able to walk only short distances with walking equipment, and require a 
wheelchair to get around the neighbourhood. 
5  Unable to walk alone, even with walking equipment. Able to walk short 
distances with the help of another person, and require a wheelchair to get 
around the neighbourhood. 





1  Full use of two hands and ten fingers. 
2  Limitations in the use of hands or fingers, but do not require special tools or 
help of another person. 
3  Limitations in the use of hands or fingers, independent with use of special tools 
(do not require the help of another person). 
4  Limitations in the use of hands or fingers, require the help of another person for 
some tasks (not independent even with use of special tools). 
5  Limitations in use of hands or fingers, require the help of another person for 
most tasks (not independent even with use of special tools). 
6  Limitations in use of hands or fingers, require the help of another person for all 
tasks (not independent even with use of special tools). 
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1  Happy and interested in life. 
2  Somewhat happy. 
3  Somewhat unhappy. 
4  Very unhappy. 





1  Able to remember most things, think clearly and solve day to day problems. 
2  Able to remember most things, but have a little difficulty when trying to think 
and solve day to day problems. 
3  Somewhat forgetful, but able to think clearly and solve day to day problems. 
4  Somewhat forgetful, and have a little difficulty when trying to think or solve 
day to day problems. 
5  Very forgetful, and have great difficulty when trying to think or solve day to 
day problems. 






1  Free of pain and discomfort. 
2  Mild to moderate pain that prevents no activities. 
3  Moderate pain that prevents a few activities. 
4  Moderate to severe pain that prevents some activities. 
5  Severe pain that prevents most activities. 
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THE DERRIFORD APPEARANCE SCALE (DAS 59) 
 
YOUR NAME  DATE 
      /    /     
YOUR DATE OF BIRTH  SEX: Male  /  Female 
    /    /       
OCCUPATION: Yours  Partner’s / Spouse’s 
   
 
YOUR FAMILY STATUS (please tick the option closest to your situation) 
Married/Living with partner  Living alone  Living with relatives/friends 





YOUR ETHNIC BACKGROUND (please tick) 
Bangladeshi    Pakistani    Black – African   
Indian    Chinese    Black – Caribbean   
White     
Other (please specify)  Black – other (please specify 
   
 
This questionnaire is concerned about how you feel about your appearance 
The first part of the scale is designed to find out if you are sensitive or self-conscious about any aspect of your appearance (even if 
this is not usually visible to others). 
(a) Is there any aspect of your appearance (however small) that concerns you at all? 
Yes / No    
If no, please turn to the next page If yes, please continue: 
(b) The aspect of my appearance about which I am most sensitive or self-conscious is 
 
From now on, we will refer to this aspect of your appearance as your ‘feature’ 
(c) The thing I do not like about my ‘feature’ is 
 
(d) If you are sensitive or concerned about any other features of your body or your appearance, please say what they are 
 
 
For each question 
Please read each statement carefully and then circle the appropriate number on the right hand side. 
If a statement does not apply to you, circle N/A. 
Please be sure to answer the whole scale: do not miss out any items. 
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For questions 1 to 33 use the scale 
1  2  3  4  N/A 
Almost never  Sometimes  Often  Almost always  Does not apply 
 
1  I am self-concious of my ‘feature’  1  2  3  4  N/A 
2  I avoid children in the street   1  2  3  4  N/A 
3  I find it difficult to make friends  1  2  3  4  N/A 
4  I avoid undressing in front of my spouse / partner  1  2  3  4  N/A 
5  At present I try to avoid going to my school / college / work   1  2  3  4  N/A 
6  I avoid going to pubs / restaurants   1  2  3  4  N/A 
7  I avoid going to parties / discos   1  2  3  4  N/A 
8  I take a special interest in what other people’s ‘feature’ looks like  1  2  3  4  N/A 
9  I avoid communal changing rooms   1  2  3  4  N/A 
10  I avoid having my photograph taken  1  2  3  4  N/A 
11  1 avoid getting my hair wet   1  2  3  4  N/A 
12  I have been hurt by other people saying things about my ‘feature’   1  2  3  4  N/A 
13  I avoid shopping in department stores   1  2  3  4  N/A 
14  I avoid going out of the house   1  2  3  4  N/A 
15  I raise the subject of my ‘feature’ in conversation before other people do  1  2  3  4  N/A 
16  I close into my shell   1  2  3  4  N/A 
17  My self-consciousness makes me  irritable at home   1  2  3  4  N/A 
18  Other people misjudge me because of my ‘feature’   1  2  3  4  N/A 
19  In the past I have tried to avoid going to school / college / work   1  2  3  4  N/A 
20  I feel an embarrassment to my friends   1  2  3  4  N/A 
21  I feel a freak   1  2  3  4  N/A 
22  I worry about my sanity   1  2  3  4  N/A 
23  My self-consciousness has an adverse effect on my sex life   1  2  3  4  N/A 
24  My self-consciousness has an adverse effect on my marriage   1  2  3  4  N/A 
25  My ‘feature’ causes me pain or discomfort   1  2  3  4  N/A 
26  My ‘feature’ physically limits my ability to do the things I want to do   1  2  3  4  N/A 
27  My ‘feature’ makes me feel unattractive   1  2  3  4  N/A 
28  My ‘feature’ makes me feel unlovable   1  2  3  4  N/A 
29  My ‘feature’ makes me feel isolated   1  2  3  4  N/A 
30  My ‘feature’ makes me feel embarrassed   1  2  3  4  N/A 
21  My ‘feature’ makes me feel inferior   1  2  3  4  N/A 
32  My ‘feature’ makes me feel rejected   1  2  3  4  N/A 
33  My ‘feature’ makes me feel useless   1  2  3  4  N/A 
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For questions 34 to 51 use the scale 
1  2  3  4  5  N/A 
Not at all distressed    Moderately distressed    Extremely distressed  Does not apply 
 
HOW DISTRESSED DO YOU GET WHEN: 
34  Other people stare at your ‘feature’  1  2  3  4  5  N/A 
35  Other people make remarks about your ‘feature’   1  2  3  4  5  N/A 
36  Other people ask about your ‘feature’   1  2  3  4  5  N/A 
37  You go to the beach   1  2  3  4  5  N/A 
38  Others see you in a particular view (eg. front, side)   1  2  3  4  5  N/A 
39  You go to your school / college / work   1  2  3  4  5  N/A 
40  You travel on public transport   1  2  3  4  5  N/A 
41  You see yourself in a mirror / window   1  2  3  4  5  N/A 
42  You meet strangers   1  2  3  4  5  N/A 
 
HOW DISTRESSED ARE YOU BY: 
43  Being unable to wear your favourite clothes   1  2  3  4  5  N/A 
44  Being unable to change your hairstyle   1  2  3  4  5  N/A 
45  Not being able to go swimming   1  2  3  4  5  N/A 
46  Not being able to play games   1  2  3  4  5  N/A 
47  Not being able to go to social events   1  2  3  4  5  N/A 
48  Being unable to answer the front door at home   1  2  3  4  5  N/A 
49  Being unable to look at yourself in the mirror   1  2  3  4  5  N/A 
50  Being unable to go to pubs / restaurants   1  2  3  4  5  N/A 
51  Not being able to go out in windy weather   1  2  3  4  5  N/A 
 
For questions 52 to 59 use the scale 
1  2  3  4  5 
Not at all  Slightly  Moderately  Greatly  Extremely 
 
IN GENERAL 
52  How confident do you feel?   1  2  3  4  5 
53  How irritable do you feel?   1  2  3  4  5 
54  How secure do you feel?   1  2  3  4  5 
55  How cheerful do you feel?   1  2  3  4  5 
56  How normal do you feel?   1  2  3  4  5 
57  How feminine / masculine do you feel?   1  2  3  4  5 
58  How hurt do you feel?   1  2  3  4  5 
59  How hostile do you feel?   1  2  3  4  5 
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Appendix 22  
CONSORT Checklist of items to include 
when reporting a randomised trialAppendix 22 
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SECTION/topic Item Description Page
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., ‘random 




2 Scientific background and explanation of rationale 1,2
METHODS 
Participants
3 Eligibility criteria for participants and the settings and locations where the 
data were collected
5,6
Interventions 4 Precise details of the interventions intended for each group and how and 
when they were actually administered
6, 7
Objectives 5 Specific objectives and hypotheses 9
Outcomes 6 Clearly defined primary and secondary outcome measures and, when 
applicable, any methods used to enhance the quality of measurements 
(e.g., multiple observations, training of assessors)
9–11
Sample size 7 How sample size was determined and, when applicable, explanation of 
any interim analyses and stopping rules
13
Randomisation – Sequence 
generation
8 Method used to generate the random allocation sequence, including 
details of any restrictions (e.g., blocking, stratification)
13
Randomisation – Allocation 
concealment
9 Method used to implement the random allocation sequence (e.g., 
numbered containers or central telephone), clarifying whether the 




10 Who generated the allocation sequence, who enrolled participants, and 
who assigned participants to their groups
13, 14
Blinding (masking) 11 Whether or not participants, those administering the interventions, and 
those assessing the outcomes were blinded to group assignment. When 
relevant, how the success of blinding was evaluated
14
Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); 






13 Flow of participants through each stage (a diagram is strongly 
recommended). Specifically, for each group report the numbers of 
participants randomly assigned, receiving intended treatment, completing 
the study protocol, and analysed for the primary outcome. Describe 
protocol deviations from study as planned, together with reasons
16
Recruitment 14 Dates defining the periods of recruitment and follow-up 15, 17, 18
Baseline data 15 Baseline demographic and clinical characteristics of each group 18
Numbers analysed 16 Number of participants (denominator) in each group included in each 
analysis and whether the analysis was by ‘intention-to-treat’. State the 
results in absolute numbers when feasible (e.g., 10/20, not 50%)
17
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for 
each group, and the estimated effect size and its precision (e.g., 95% 
confidence interval)
18–21
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including 
subgroup analyses and adjusted analyses, indicating those prespecified 
and those exploratory
25
Adverse events 19 All important adverse events or side effects in each intervention group 25,26
DISCUSSION 
Interpretation
20 Interpretation of the results, taking into account study hypotheses, 
sources of potential bias or imprecision and the dangers associated with 
multiplicity of analyses and outcomes
47, 48
Generalisability 21 Generalisability (external validity) of the trial findings 47, 48
Overall evidence 22 General interpretation of the results in the context of current evidence 48, 49DOI: 10.3310/hta13470  Health Technology Assessment 2009; Vol. 13: No. 47
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